UNSPSC 85816224: Introduction of monoclonal antibody into peripheral vein, open approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of monoclonal antibody into peripheral vein, open approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0300M

UNSPSC 85816224 Introduction of monoclonal antibody into peripheral vein, open approach is a Commodity code with minimal recent state and local procurement activity directly aligned with its clinical procedure nomenclature. The source contains no recent solicitations for intravenous monoclonal antibody administration services; instead, the opportunities tagged to this code reflect a mismatch between the UNSPSC designation and actual procurement scope. State and local governments are not soliciting specific procedure-code services under this Commodity; the few opportunities nominally associated with it (such as virtual urgent care, medical services, occupational health, and employee wellness platforms) span telehealth operations, occupational medicine, occupational health screenings, behavioral health services, and administrative wellness platforms—none involving the targeted clinical procedure. This suggests either a data-entry error in how opportunities were classified or a fundamental misalignment between the Commodity code's procedural specificity and how state and local buyers actually structure healthcare service solicitations.

The geographic spread of tangentially related opportunities spans California, Georgia, Nevada, Colorado, Florida, and multiple additional states, but this distribution does not indicate meaningful market activity under the code itself. Issuing bodies include state health authorities (Nevada Health Authority), county departments (DeKalb County Georgia; San Mateo County; Boulder County; Rockland County), cities (Ocala, Phoenix), and special-purpose health agencies, yet none are procuring monoclonal antibody infusion services. The code shows little relevant recent activity and should not be pursued as a meaningful business development target without clarification of how state and local procurement offices actually use this Commodity designation in practice.